Marizyme Financials
| MRZM Stock | USD 0.05 0.00 0.00% |
With this module, you can analyze Marizyme financials for your investing period. You should be able to track the changes in Marizyme individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Marizyme |
The data published in Marizyme's official financial statements typically reflect Marizyme's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Marizyme's quantitative information. For example, before you start analyzing numbers published by Marizyme accountants, it's essential to understand Marizyme's liquidity, profitability, and earnings quality within the context of the Software space in which it operates.
Marizyme Stock Summary
Marizyme competes with Aerovate Therapeutics, Akari Therapeutics, Armata Pharmaceuticals, Anebulo Pharmaceuticals, and Processa Pharmaceuticals. Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida. Marizyme operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| ISIN | US5703721028 |
| Business Address | 555 Heritage Drive, |
| Sector | Software |
| Industry | Information Technology |
| Benchmark | Dow Jones Industrial |
| Website | marizyme.com |
| Phone | 561 935 9955 |
| Currency | USD - US Dollar |
Marizyme Key Financial Ratios
There are many critical financial ratios that Marizyme's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Marizyme reports annually and quarterly.Marizyme Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Marizyme's current stock value. Our valuation model uses many indicators to compare Marizyme value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Marizyme competition to find correlations between indicators driving Marizyme's intrinsic value. More Info.Marizyme is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Marizyme's earnings, one of the primary drivers of an investment's value.Marizyme Systematic Risk
Marizyme's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Marizyme volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Marizyme correlated with the market. If Beta is less than 0 Marizyme generally moves in the opposite direction as compared to the market. If Marizyme Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Marizyme is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Marizyme is generally in the same direction as the market. If Beta > 1 Marizyme moves generally in the same direction as, but more than the movement of the benchmark.
Marizyme March 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Marizyme help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Marizyme. We use our internally-developed statistical techniques to arrive at the intrinsic value of Marizyme based on widely used predictive technical indicators. In general, we focus on analyzing Marizyme OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Marizyme's daily price indicators and compare them against related drivers.
| Downside Deviation | 29.86 | |||
| Information Ratio | 0.1022 | |||
| Maximum Drawdown | 1150.0 | |||
| Value At Risk | (25.00) | |||
| Potential Upside | 2.13 |
Other Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.